TY - JOUR AU - Fu, Lin AU - Shang, Xiaoyang AU - Zhang, Xiaoshan PY - 2020/05/21 Y2 - 2024/03/28 TI - The Impact of Atorvastatin on Cardiac Performance for Dilated Cardiomyopathy: A Meta-analysis of Randomized Controlled Studies JF - The Heart Surgery Forum JA - HSF VL - 23 IS - 3 SE - DO - 10.1532/hsf.2787 UR - https://journal.hsforum.com/index.php/HSF/article/view/2787 SP - E329-E334 AB - <p class="p1"><span class="s1"><strong>Introduction:</strong> The efficacy of atorvastatin for dilated cardiomyopathy remains controversial. We conducted a systematic review and meta-analysis to explore the influence of atorvastatin on cardiac performance for dilated cardiomyopathy.</span></p><p class="p1"><span class="s1"><strong>Methods:</strong> We searched PubMed, Embase, Web of <br />Science, EBSCO, and Cochrane library databases through February 2019 for randomized controlled trials (RCTs) assessing the effect of atorvastatin on cardiac performance for dilated cardiomyopathy. This meta-analysis was performed using the random-effects model.</span></p><p class="p1"><strong>Results:</strong> Five RCTs involving 401 patients were included in the meta-analysis. Overall, compared with control groups for dilated cardiomyopathy, atorvastatin treatment resulted in a significantly positive impact on left ventricular ejection fraction (standard mean difference [SMD] = 0.58; 95% confidence interval [CI] = 0.33 to 0.84; <em>P</em> &lt; .00001), 6-minute walk test (SMD = 0.79; 95% CI = 0.27 to 1.31; <em>P</em> = .003), N-terminal pro-brain natriuretic peptide (SMD = –0.60; 95% CI = –1.18 to –0.01; <em>P</em> = .04), left ventricular systolic volume (SMD = 0.41; 95% CI = 0.03 to 0.79; <em>P</em> = .03), low-density lipoprotein (SMD = –1.37; 95% CI = –1.92 to –0.82; <em>P</em> = .00001), and C-reactive protein (SMD = –0.47; 95% CI = –0.72 to –0.22; <em>P</em> = .0002), but showed no obvious influence on left ventricular end-diastolic volume (SMD = 0.14; 95% CI = –0.37 to 0.64; <em>P</em> = .59).</p><p class="p1"><span class="s1"><strong>Conclusions:</strong> Atorvastatin treatment provides significant benefits for dilated cardiomyopathy.</span></p> ER -